Plain-English translation of NCT07668271 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is evaluating the Recombinant Human Papillomavirus 9-valent Vaccine (Escherichia Coli) — a vaccine designed to protect against nine types of HPV that can cause cervical cancer and other diseases. The study is checking whether three different batches of this medication produce consistent immune responses in women's bodies. This helps ensure the vaccine works the same way, no matter which batch you receive.
Vaccine manufacturers need to prove that every batch they produce works equally well and safely. This trial ensures that this medication meets international quality standards so it can be approved for use in different countries.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic five times over seven months and receive three doses of the vaccine at months 0, 1, and 6. You'll have blood drawn twice (at the start and at month 7) to measure your immune response. After each vaccination, you'll keep a simple diary of any side effects for 30 days and report any serious reactions to the study team. The entire commitment involves about five clinic visits and some home monitoring.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China